tetano
Editor, Senior Moderator
Zh Mikrobiol Epidemiol Immunobiol. 2011 Jul-Aug;(4):76-80.
[Postvaccination immunity against influenza in patients with chronic broncho-pulmonary pathology].
[Article in Russian]
[No authors listed]
Abstract
AIM:
Evaluation of postvaccination immunity against influenza in patients with bronchopulmonary pathology.
MATERIALS AND METHODS:
22 patients with broncho-pulmonary pathology vaccinated against influenza with Grippol plus preparation participated in the study. Rates of influenza and acute respiratory illnesses (ARI), rates and duration of exacerbations of the underlying disease were tracked based on medical documents. Hemagglutination inhibition reaction in paired sera before and 6 and 12 months after the vaccination was used to evaluate vaccine immunogenicity.
RESULTS:
None of the patients had influenza diagnosis for one year. A reduction of ARI rate of 37% was detected. Rate of exacerbation of the underlying disease decreased by 1.9 times, duration of exacerbations--by 2 times. Data on immunogenicity against A/H1N1/ Brisbane/59/07, A/H3N2/Uruguay/716/2007, B/ Florida/4/2006 are presented. Immunogenicity against B/Brisbane/60/2008 strain not contained in the vaccine was insufficient to induce adequate protection. Statistically significant differences were not detected during comparison of immunogenicity in patients with broncho-pulmonary pathology and healthy people.
CONCLUSION:
Grippol plus vaccine in patients with respiratory tract diseases is immunogenic and renders clinical effect by reducing influenza morbidity and rate of exacerbation of the underlying disease.
PMID:
21913396
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21913396
[Postvaccination immunity against influenza in patients with chronic broncho-pulmonary pathology].
[Article in Russian]
[No authors listed]
Abstract
AIM:
Evaluation of postvaccination immunity against influenza in patients with bronchopulmonary pathology.
MATERIALS AND METHODS:
22 patients with broncho-pulmonary pathology vaccinated against influenza with Grippol plus preparation participated in the study. Rates of influenza and acute respiratory illnesses (ARI), rates and duration of exacerbations of the underlying disease were tracked based on medical documents. Hemagglutination inhibition reaction in paired sera before and 6 and 12 months after the vaccination was used to evaluate vaccine immunogenicity.
RESULTS:
None of the patients had influenza diagnosis for one year. A reduction of ARI rate of 37% was detected. Rate of exacerbation of the underlying disease decreased by 1.9 times, duration of exacerbations--by 2 times. Data on immunogenicity against A/H1N1/ Brisbane/59/07, A/H3N2/Uruguay/716/2007, B/ Florida/4/2006 are presented. Immunogenicity against B/Brisbane/60/2008 strain not contained in the vaccine was insufficient to induce adequate protection. Statistically significant differences were not detected during comparison of immunogenicity in patients with broncho-pulmonary pathology and healthy people.
CONCLUSION:
Grippol plus vaccine in patients with respiratory tract diseases is immunogenic and renders clinical effect by reducing influenza morbidity and rate of exacerbation of the underlying disease.
PMID:
21913396
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21913396